Okada H - Search Results

1

The role of emerging therapy in the management of patients with diffuse low grade glioma.

Sloan AE, Okada H, Ryken TC, Kalkanis SN, Olson JJ. Sloan AE, et al. Among authors: okada h. J Neurooncol. 2015 Dec;125(3):631-5. doi: 10.1007/s11060-015-1865-3. Epub 2015 Nov 3. J Neurooncol. 2015. PMID: 26530260 Review.

2

Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy.

Okada H, Lieberman FS, Edington HD, Witham TF, Wargo MJ, Cai Q, Elder EH, Whiteside TL, Schold SC Jr, Pollack IF. Okada H, et al. J Neurooncol. 2003 Aug-Sep;64(1-2):13-20. doi: 10.1007/BF02700016. J Neurooncol. 2003. PMID: 12952282

3

Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo.

Witham TF, Villa L, Yang T, Pollack IF, Okada H, Robbins PD, Chambers WH. Witham TF, et al. Among authors: okada h. J Neurooncol. 2003 Aug-Sep;64(1-2):63-9. doi: 10.1007/BF02700021. J Neurooncol. 2003. PMID: 12952287

4

Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas.

Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF. Okada H, et al. J Neurooncol. 2008 Jul;88(3):245-50. doi: 10.1007/s11060-008-9566-9. Epub 2008 Mar 7. J Neurooncol. 2008. PMID: 18324354 Free PMC article.

5

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.

Zhu X, Fujita M, Snyder LA, Okada H. Zhu X, et al. Among authors: okada h. J Neurooncol. 2011 Aug;104(1):83-92. doi: 10.1007/s11060-010-0473-5. Epub 2010 Nov 30. J Neurooncol. 2011. PMID: 21116835 Free PMC article.

6

Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy.

Yeung JT, Hamilton RL, Okada H, Jakacki RI, Pollack IF. Yeung JT, et al. Among authors: okada h. J Neurooncol. 2013 Jan;111(2):103-11. doi: 10.1007/s11060-012-0998-x. Epub 2012 Nov 21. J Neurooncol. 2013. PMID: 23179498 Free PMC article.

7

Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials.

Reardon DA, Okada H. Reardon DA, et al. Among authors: okada h. J Neurooncol. 2015 Jul;123(3):339-46. doi: 10.1007/s11060-015-1748-7. Epub 2015 Feb 24. J Neurooncol. 2015. PMID: 25707876

8

Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.

Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H. Pollack IF, et al. Among authors: okada h. Neuro Oncol. 2016 Aug;18(8):1157-68. doi: 10.1093/neuonc/now026. Epub 2016 Mar 15. Neuro Oncol. 2016. PMID: 26984745 Free PMC article.

9

Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.

Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H. Pollack IF, et al. Among authors: okada h. J Neurooncol. 2016 Dec;130(3):517-527. doi: 10.1007/s11060-016-2245-3. Epub 2016 Sep 13. J Neurooncol. 2016. PMID: 27624914 Free PMC article.

10

Is the immune response a friend or foe for viral therapy of glioma?

Okada H, Thorne SH. Okada H, et al. Neuro Oncol. 2017 Jul 1;19(7):882-883. doi: 10.1093/neuonc/nox082. Neuro Oncol. 2017. PMID: 28874006 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,627 results

Search Page

Filters